KIDS

KIDS

USD

OrthoPediatrics Corp. Common Stock

$21.540-0.610 (-2.754%)

Prix en Temps Réel

Healthcare
Dispositifs médicaux
États-Unis

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$22.150

Haut

$22.240

Bas

$21.050

Volume

0.02M

Fondamentaux de l'Entreprise

Capitalisation Boursière

540.3M

Industrie

Dispositifs médicaux

Pays

United States

Statistiques de Trading

Volume Moyen

0.23M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $20.247Actuel $21.540Haut $35.99

Rapport d'Analyse IA

Dernière mise à jour: 15 avr. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

[KIDS: OrthoPediatrics Corp. Common Stock]: Decoding the Signals - What's Next?

Stock Symbol: KIDS Generate Date: 2025-04-15 08:02:36

Let's take a look at OrthoPediatrics (KIDS). This company focuses on medical devices for kids' orthopedic issues – think broken bones, scoliosis, that sort of thing. Recent news and stock movements are giving us some interesting clues about where things might be headed.

Recent News Buzz: A Mixed Bag, But Leaning Up?

The news feed for KIDS is a bit of a mixed bag, but if you squint, you might see more green shoots than weeds. Here's the gist:

  • Analyst Price Targets are All Over the Place: We've got analysts saying "Hold" with a lowered price target of $24 (Truist), but others shouting "Buy" with targets way higher at $42 (Needham), $37 (Lake Street), and even $50 (Citizens). It's like a price target buffet! The average of these 'Buy' targets is significantly above where the stock is currently trading. This suggests some experts think it's undervalued.
  • New Product is a Good Sign: They just launched a new system for scoliosis called VerteGlide™. New products are generally good news for medical device companies – it means they're innovating and trying to grow. Scoliosis is a significant market, so this could be a real driver.
  • "Best Places to Work" - So What?: They got an award for being a good place to work in Indiana. Nice for them, and maybe it helps attract talent, but it's not exactly moving the needle on stock price directly. Still, happy employees can mean a more productive company long term.
  • Conference Chatter: They participated in a healthcare conference. This is pretty standard stuff for public companies. It's a chance to get their story out to investors, but not a major event on its own.

Overall News Vibe: While one analyst lowered their price target (and kept a "Hold" rating), the majority of analyst activity is positive ("Buy" or "Market Outperform") with significantly higher price targets. The new product launch is a concrete positive development. So, the news leans towards being cautiously optimistic, despite the mixed analyst opinions.

Price Check: Bouncing Around Near the Bottom?

Looking at the stock price over the last month or so, it's been a bit of a rollercoaster, mostly trending downwards recently.

  • Downwards Drift: If you look back to mid-January, the price was in the $25-$27 range. Now, in mid-April, it's hovering around $21. That's a noticeable dip. The last few days especially have seen a bit of a slide.
  • 52-Week Low Territory: The stock is currently trading very close to its 52-week low of $20.37. This could be seen as either a bad sign (hitting new lows) or a potential opportunity (buying near the bottom).
  • AI Thinks... Up?: Interestingly, the AI prediction model thinks the price will nudge up slightly in the next couple of days (a few percentage points). It's not a massive jump, but it's predicting upward movement, even if just a little.

Price Action Summary: Recent price action is weak, near 52-week lows. However, the AI prediction offers a glimmer of short-term upside, and the longer-term analyst price targets are much higher. It's a picture of short-term pain, potentially longer-term gain.

Outlook & Strategy Ideas: Patience Might Pay Off, But Watch Closely

Putting it all together, what's the takeaway for someone looking at KIDS stock?

  • Near-Term Leaning: Cautious Hold/Accumulate. The recent price drop and mixed analyst opinions suggest caution is warranted. However, the significantly higher average analyst price target, the new product launch, and even the AI's slight positive prediction offer reasons for optimism. It might be a time to start accumulating shares slowly if you believe in the company's long-term potential, but definitely not a time to go all-in.
  • Potential Entry Consideration: Around the Current Price ($21-$22). Given the stock is near its 52-week low and the AI predicts a slight uptick, the current price range could be considered a potential entry point for long-term investors. If the price dips further towards the 52-week low ($20.37), that could be another area to watch for potential entry, as it might represent strong support.
  • Potential Exit/Stop-Loss Consideration: Below $20 (Stop-Loss) and $24-$25 (Initial Profit Target). To manage risk, a stop-loss order below the 52-week low, say around $20, could be smart. If the stock does start to recover, an initial profit target could be around the $24-$25 range, which is where the recent price action has seen some resistance and also aligns with the lower analyst price target. For a bigger potential upside, you'd be looking towards the higher analyst targets in the $37-$50 range, but that's a longer-term game.

Company Context Matters: Remember, OrthoPediatrics is in the medical device industry, specifically focused on kids. This sector can be defensive (people still need medical care even in economic downturns). Their focus on pediatrics gives them a niche market. The scoliosis market, which they are expanding into with their new product, is a significant area within pediatric orthopedics. Keep an eye on news related to medical device sales, hospital procedures, and any developments in pediatric healthcare.

In short: KIDS looks like a mixed bag right now. Short-term price action is weak, but analyst sentiment and AI predictions offer some hope. It might be a stock for patient investors who believe in the long-term potential of pediatric orthopedics and are willing to ride out some short-term bumps. Definitely do your own digging and see if it fits your investment style.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am acting as an analyst interpreting publicly available data. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Actualités Connexes

Analyst Upgrades

Truist Securities Maintains Hold on OrthoPediatrics, Lowers Price Target to $24

Truist Securities analyst Richard Newitter maintains OrthoPediatrics with a Hold and lowers the price target from $26 to $24.

Voir plus
Truist Securities Maintains Hold on OrthoPediatrics, Lowers Price Target to $24
Analyst Upgrades

Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target

Needham analyst Mike Matson reiterates OrthoPediatrics with a Buy and maintains $42 price target.

Voir plus
Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target
GlobeNewswire

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

Voir plus
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
Analyst Upgrades

Lake Street Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $37

Lake Street analyst Ben Haynor initiates coverage on OrthoPediatrics with a Buy rating and announces Price Target of $37.

Voir plus
Lake Street Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $37
GlobeNewswire

OrthoPediatrics Corp. to Participate in the 24th Annual Needham Virtual Healthcare Conference

WARSAW, Ind., March 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

Voir plus
OrthoPediatrics Corp. to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire

OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana

WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

Analyst Upgrades

Citizens Capital Markets Reiterates Market Outperform on OrthoPediatrics, Maintains $50 Price Target

Citizens Capital Markets analyst David Turkaly reiterates OrthoPediatrics with a Market Outperform and maintains $50 price target.

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 28 avr. 2025, 04:52

BaissierNeutreHaussier

73.0% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
ValeurCroissance
Guide de Trading

Point d'Entrée

$21.33

Prise de Bénéfices

$23.42

Stop Loss

$19.39

Facteurs Clés

Le PDI 16.4 est au-dessus du MDI 7.4 avec un ADX de 12.8, suggérant une tendance haussière
Le cours actuel est proche du niveau de support ($21.24), indiquant une opportunité d'achat potentielle
Le volume de transactions est 7.6x la moyenne (2,333), indiquant une pression d'achat extrêmement forte
Le MACD 0.0078 est au-dessus de la ligne de signal -0.0258, indiquant un croisement haussier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.